Spanish Regulator Suspends Manufacturing Authorization of Drugmaker for GMP Lapses

Spain’s Agency of Medicines and Medical Devices has ordered Madrid vaccine maker Angulema to suspend manufacturing and recall drug batches over GMP deficiencies.

The critical and major deficiencies observed in a November inspection concern the quality system and manufacturing process for immunological medicines — such as the company’s subcutaneous sterile bacterial and allergenic vaccines, the AEMPS said.

Angulema failed to implement an effective pharmaceutical quality system to ensure vaccines met production standards.

Angulema is prohibited from supplying batches and must recall all batches already distributed in Spain. It faces a full suspension on its manufacturing authorization and temporary suspension on its importation authorization, the AEMPS said.